Apricus Biosciences Inc (NASDAQ:APRI) was the recipient of a significant decrease in short interest in September. As of September 28th, there was short interest totalling 1,041,203 shares, a decrease of 29.4% from the September 14th total of 1,474,242 shares. Based on an average daily volume of 426,171 shares, the days-to-cover ratio is presently 2.4 days. Approximately 4.6% of the company’s stock are sold short.

Shares of APRI opened at $0.31 on Tuesday. The company has a market capitalization of $7.27 million, a P/E ratio of -0.31 and a beta of 1.22. Apricus Biosciences has a 52-week low of $0.25 and a 52-week high of $3.34.

Apricus Biosciences (NASDAQ:APRI) last announced its quarterly earnings results on Thursday, August 9th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.04. Equities analysts anticipate that Apricus Biosciences will post -0.4 EPS for the current fiscal year.

Apricus Biosciences Company Profile

Apricus Biosciences, Inc, a biopharmaceutical company, focuses on the development of product candidates in the areas of urology and rheumatology. The company develops Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction; and RayVa, which is in Phase IIa clinical trial to treat Raynaud's phenomenon associated with scleroderma.

Read More: Asset Allocation, Balancing Your Investments

Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.